Cynapsus Therapeutics Inc Stock

Stocks

Delayed Toronto S.E. Other stock markets			5-day change	1st Jan Change
- ^CAD	-.--%		+0.21%	-

03/06	HyProMag Ltd is 100% Owned by Maginito Ltd, Which is Owned on a 79.4%/20.6% Basis by Mkango Resources and CoTec	MT
03/06	HyProMag USA LLC is Owned 50:50 by CoTec and HyProMag Limited	MT

03/06	HyProMag Ltd is 100% Owned by Maginito Ltd, Which is Owned on a 79.4%/20.6% Basis by Mkango Resources and CoTec	MT
03/06	HyProMag USA LLC is Owned 50:50 by CoTec and HyProMag Limited	MT
03/06	CoTec JV, HyProMag USA, to Commence Preparatory Work for Project Execution Phase at Dallas-Fort Worth Texas Hub	MT
20/05	CoTec Releases Updated Mineral Resource and "Positive" PEA for Lac Jeannine Iron Tailings Project; Lost Near 10% on Tuesday	MT
12/03/24	Mkango and CoTec Brief: Mkango Subsidiary, Maginito, And CoTec Appointed Lead Engineers BBA And Pegasus To Complete Feasibility Study for HyProMag USA	MT
30/01/24	CoTec Holdings Outlines Key Targets For 2024	MT
04/01/24	Mkango Surges Near 12% As Forms HyProMag Joint Venture In US With CoTec	MT
11/10/23	Mkango Surges 11% As Says To Commence Feasibility Study For Proposed US Operation With CoTec	MT
10/10/23	Mkango, CoTec To Commence Feasibility Study For Proposed US Operation	MT
02/10/23	CoTec Completed Conversion of 2 Million Pounds Mkango Loan Note to Double Equity Position in Maginito to 20.6%	MT
15/09/23	Mkango Down Near 3% As Agrees To Form US Joint Venture With CoTec Holdings	MT
14/09/23	CoTec Holdings, Mkango To Form US Joint Venture	MT
30/06/23	Kings Chapel Increases Stake In CoTec Holdings	MT

06/05	COPPER INTELLIGENCE TO FORM AN EARLY-STAGE EXPLORATION JOINT VENTURE WITH COTEC TO TARGET PROCESSING HISTORICAL COPPER TAILINGS OPPORTUNITIES IN THE DEMOCRATIC REPUBLIC OF CONGO	PR
01/09/16	Cynapsus Therapeutics : Sunovion Pharmaceuticals to Acquire Cynapsus Therapeutics	PU
29/08/16	Cynapsus Therapeutics : Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease	GL
15/08/16	Cynapsus Therapeutics : Announces Positive Opinion from Data and Safety Monitoring Board on Phase 3 Parkinson's Disease Clinical Study Allowing for At-Home Titration	GL
12/08/16	Cynapsus Therapeutics : Announces Publication in the Journal Movement Disorders of Data for the Treatment of OFF Episodes in Patients with Parkinson's Disease	GL

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CYNAPSUS THERAPEUTICS INC	-.--%	+0.21%	-	-	0
WUXI APPTEC CO., LTD.	-7.17%	-4.39%	+45.51%	+79.00%	52.1B
ARGENX SE	+0.24%	-1.54%	+53.22%	+71.85%	53.83B
INSMED INCORPORATED	+0.80%	-6.31%	+3.98%	+423.29%	23.48B
BIONTECH SE	-0.09%	-0.01%	-17.62%	-14.67%	23.13B
WUXI BIOLOGICS (CAYMAN) INC.	-5.95%	-2.58%	+30.67%	-9.58%	19.36B
GENMAB A/S	-1.14%	+0.03%	+31.57%	-30.42%	17.56B
PHARMAESSENTIA CORPORATION	-5.16%	-7.00%	+168.44%	+306.37%	15.2B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-6.91%	-5.83%	+26.53%	+636.97%	14.83B
EXELIXIS, INC.	+0.43%	-1.03%	+24.63%	+191.40%	14.06B
Average	-2.50%	-2.62%	+40.77%	+183.80%	25.95B
Weighted average by Cap.	-2.80%	-2.36%	+40.12%	+144.11%